These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1539293)

  • 1. Treatment with poly- and monoclonal antilymphocyte antibodies: assessment of efficacy and safety in transplantation.
    Claesson K; Tufveson G; Wahlberg J
    Transplant Proc; 1992 Feb; 24(1):314. PubMed ID: 1539293
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
    Alamartine E; Bellakoul R; Berthoux F
    Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of steroid resistant acute rejection after renal transplantation.
    Oh CK; Kim YS; Kim MS; Kim SI; Park K
    Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
    [No Abstract]   [Full Text] [Related]  

  • 4. Prophylaxis with a short course of OKT3 in renal transplantation: comparative analysis with recipients treated either with prophylactic ATG or with CyA.
    Lloveras J; Puig JM; Oliveras A; Orfila A; Comerma I; Aubia J; Masramón J
    Transplant Proc; 1992 Feb; 24(1):43-4. PubMed ID: 1539335
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients.
    Klauser R; Zlabinger GJ; Traindl O; Franz M; Watschinger B; Pohanka E; Kudlacek S; Kovarik J
    Transplant Proc; 1992 Feb; 24(1):292-4. PubMed ID: 1539284
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytokine nephropathy during antilymphocyte therapy.
    Batiuk TD; Bennett WM; Norman DJ
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):27-30. PubMed ID: 8465418
    [No Abstract]   [Full Text] [Related]  

  • 8. Late acute rejection in renal transplant recipients: response to steroid treatment.
    Prieto C; Pulido F; Rodríguez-Paternina E; Algranati C; Bello I; Farias J; G-Millet V
    Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
    [No Abstract]   [Full Text] [Related]  

  • 9. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
    Shield CF
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
    [No Abstract]   [Full Text] [Related]  

  • 10. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
    Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ
    Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 12. Prospective trial of OKT3 for early prophylaxis of rejection in immunologic "high risk" renal transplant recipients: long-term results.
    Pomer S; Waldherr R; Möhring K; Kempter F; Wiesel M; Weimer R
    Transplant Proc; 1992 Oct; 24(5):1732-3. PubMed ID: 1412815
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of infections in renal transplant recipients treated with cyclosporine.
    Carmellini M; Romagnoli J; Pietrabissa A; Di Stefano R; Oleggini M; Rindi P; Rizzo G; Mosca F
    Transplant Proc; 1994 Oct; 26(5):2658-9. PubMed ID: 7940832
    [No Abstract]   [Full Text] [Related]  

  • 14. Triple drug maintenance therapy in renal transplantation.
    Pallardó LM; Sánchez J; Hernandez M; Górriz JL; Sánchez P; Beneyto I; Rochera A
    Transplant Proc; 1992 Feb; 24(1):58-9. PubMed ID: 1539343
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody therapy in steroid-resistant rejection.
    Waiser J; Budde K; Schreiber M; Böhler T; Löbermann LA; Neumayer HH
    Transplant Proc; 1998 Aug; 30(5):1778-9. PubMed ID: 9723279
    [No Abstract]   [Full Text] [Related]  

  • 16. Prophylactic OKT3 monoclonal antibody versus antilymphocyte globulins: a prospective, randomized study in 148 first cadaver kidney grafts.
    Broyer M; Gagnadoux MF; Guest G; Arsan A; Beurton D; Revillon Y; Niaudet P
    Transplant Proc; 1993 Feb; 25(1 Pt 1):570-1. PubMed ID: 8438418
    [No Abstract]   [Full Text] [Related]  

  • 17. A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results.
    Baldi A; Malaise J; Mourad M; Squifflet JP
    Transplant Proc; 2000 Mar; 32(2):429-31. PubMed ID: 10715467
    [No Abstract]   [Full Text] [Related]  

  • 18. Renal transplantation with cyclosporine in the elderly population.
    Velez RL; Brinker KR; Vergne-Marini PJ; Nesser DA; Long DL; Trevino G; Dickerman RM; Helfrich GB
    Transplant Proc; 1991 Apr; 23(2):1749-52. PubMed ID: 1905073
    [No Abstract]   [Full Text] [Related]  

  • 19. Posttransplant lymphoproliferative disorders in liver recipients treated with OKT3 or ALG induction immunosuppression.
    McAlister V; Grant D; Roy A; Yilmaz Z; Ghent C; Wall W
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1400-1. PubMed ID: 8442154
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytokine-release syndrome: differences between high and low doses of OKT3.
    Norman DJ; Kimball JA; Barry JM
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.